相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- Locus Biosciences and Viatris have entered a research collaboration to develop precision engineered bacteriophage therapeutics targeting bacterial pathogens responsible for serious eye infections. - The partnership addresses high unmet medical need in ophthalmology due to rising antibiotic-resistant infections worldwide. - Locus's proprietary platform integrates predictive AI, high-throughput robotics, and synthetic biology to create bacteriophage cocktails that selectively eliminate pathogenic bacteria while sparing beneficial species. - The collaboration represents growing global recognition of phage therapy as a promising alternative to traditional antibiotics amid decades of chronic under-investment in novel antibacterial approaches.
- Excision BioTherapeutics' EBT-101 becomes the first CRISPR therapy for HIV to enter human testing, marking a major milestone for gene editing in infectious diseases. - The Cas9-based therapy demonstrated favorable safety and tolerability in Phase I/II trials, though it does not eliminate HIV entirely from infected cells. - Multiple CRISPR-based approaches are advancing through clinical development, including BD-111 for herpes infections and phage-based therapies targeting drug-resistant bacteria. - Key challenges remain in delivery mechanisms, immune responses, and regulatory frameworks for these emerging gene editing therapeutics.
- CRISPR Medicine News tracks approximately 250 clinical trials involving gene-editing therapeutic candidates as of February 2025, with more than 150 trials currently active across diverse therapeutic areas. - CASGEVY became the first approved CRISPR-based therapy in 2023, receiving regulatory clearance in multiple regions for treating sickle cell disease and beta thalassemia through foetal haemoglobin induction. - Gene editing for blood disorders continues to lead the clinical landscape, with the majority of Phase 3 trials targeting sickle cell disease and beta thalassemia, while Phase 3 trials are also underway in hereditary amyloidosis and immunodeficiencies. - Clinical applications now span 15+ therapeutic areas including blood cancers, viral diseases, metabolic disorders, autoimmune diseases, inherited eye diseases, cardiovascular disease, and neurological conditions.
• BARDA has provided $24 million in funding to Locus Biosciences as part of a larger $85 million award to advance LBP-EC01, a CRISPR-engineered bacteriophage therapy for resistant E. coli infections. • The novel therapy, which combines bacteriophage technology with CRISPR/Cas3 gene-editing, has shown promising results in phase 1b trials and is currently undergoing phase 2 evaluation in the ELIMINATE trial. • With UTIs affecting 150 million people annually and 80% caused by E. coli, this innovative approach addresses an urgent public health threat identified by both the CDC and WHO.
• CRISPR-Cas9 gene editing has achieved a significant milestone with FDA approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia. • Clinical trials are underway for CRISPR-based therapies targeting urinary tract infections, hereditary transthyretin amyloidosis, hereditary angioedema, and cardiovascular diseases. • CRISPR technology is being explored for chronic conditions like type 1 diabetes, systemic lupus erythematosus, and HIV, with early trials showing potential for disease management. • Challenges remain in addressing the high costs of CRISPR therapies and establishing regulatory standards to manage potential off-target effects and ethical implications.
- CRISPR-based therapies are entering a new phase with the first approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia. - Financial pressures are causing CRISPR-focused companies to narrow their focus on late-stage clinical trials and delay the development of new treatments. - Clinical trials are underway for blood disorders, chronic bacterial infections, protein-folding diseases, inflammatory diseases, cancers, cardiovascular disease, HIV/AIDS, diabetes and autoimmune diseases. - Innovative regulatory approaches and platform technologies could help expand the pipeline of CRISPR therapies, especially for rare diseases.
• Leading pharmaceutical companies including Merck, Pfizer, and SNIPR Biome will convene in Boston to discuss advancements in bacteriophage therapy development and clinical applications. • The summit will focus on addressing clinical translatability challenges and exploring bioinformatics applications for improved phage therapy sequencing and data processing. • Industry experts from 90+ organizations will collaborate to demonstrate clinical utility of bacteriophage therapies and forge partnerships in combating antimicrobial resistance.
